oxiconazole
Trade name: oxistat
Approved
Dec 30, 1988
Oxiconazole nitrate is 2',4'-dichloro-2-imidazol-1-ylacetophenone (Z)-[0-(2,4-dichlorobenzyl)oxime], mononitrate is an imidazole derivative characterized by a broad fungistatic spectrum. In vitro oxiconazole is highly effective against many dermatophytes, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, and Epidermophyton floccosum. In addition, fungicidal activity of various degree was found in selected species (Aspergillus fumigatus, Cryptococcus neoformans, Candida albicans and Trichophyton mentagrophytes). Synthesis of DNA was inhibited by subinhibitory concentrations of oxiconazole in parallel to cell multiplication, whereas synthesis of RNA, protein and carbohydrate was decreased to a lesser extent. OXISTAT® (Oxiconazole nitrate) Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur. Oxiconazole cream exerts no detectable systemic effect since only a negligible amount is absorbed from the skin. Once-daily use of oxiconazole cream could be valuable in patients with a history of noncompliance with multiple-daily regimens of other topical antifungal agents. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 4 marketing orgs
Earliest trial started Nov 1, 2011 (NCT01519752)
Timeline
1980s
- Dec 30, 1988
Earliest FDA Approval
- Dec 30, 1988
Fougera — NDA Secondary Org
1990s
- Sep 30, 1992
Ani Pharmaceuticals — Marketing Organization
- Sep 30, 1992
Ani Pharmaceuticals — NDA Secondary Org
- Dec 30, 1998
Fougera — First NDA Organization
- Dec 30, 1998
Fougera — NDA Organization
2010s
- Jan 1, 2011
Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)
- Mar 7, 2016
Taro Pharmaceuticals — Marketing Organization
- Mar 7, 2016
Sun Pharmaceuticals — Marketing Organization
Indications
Studied for
Mechanism of action
- Cytochrome P450 51INHIBITOR
ERG11 inhibitor
Approval history
- approvedDec 30, 1988
Chemistry & pharmacology
SMILES
Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1- Mol. weight
- 429.13 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL1262 ↗
- WikipediaOxiconazole ↗
- NCATSC668Q9I33J ↗
- ChEMBLCHEMBL1200836 ↗
Also known as
- ethanone, 1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)-, o-((2,4-dichlorophenyl)methyl)oxime, (z)-, mononitrate
- fonx
- gyno-myfungar
- myfungar
- oceral
- oceral
- oceral
- oxiconazol
- oxiconazol
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole
- oxiconazole mononitrate, (z)-isomer
- oxiconazole nitrate
- oxiconazole nitrate
- oxiconazole nitrate
- oxiconazole nitrate
- oxiconazole nitrate
- oxiconazolum
- oxiconazolum
- oxistat
- oxistat
- oxistat
- oxistat
- oxizole
- oxizole
- oxizole
- oxyconazole
- oxyconazole
- oxyconazole
- oxyconazole
- oxyconazole
- oxyconazole
- ro 13-8996
- ro-138996
- ro-138996
- ro-13-8996
- salongo
- sgd 301-76
- sgd 301-76
- sgd 301-76
- sgd-301-76
- sgd-301-76
- st-813
- st-813
- (z)-1-(2,4-dichlorophenyl)-2-(1h-imidazol-1-yl)-o-(2,4-dichlorobenzyl) ethanone oxime nitrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03823040 | Phase 1 | Jul 16, 2018 | Minia University |
| NCT01519752 | Phase 1 | Nov 1, 2011 | Taro Pharmaceuticals |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minia University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Taro Pharmaceuticals | For profit | 1 | 1 | 1 | 2011 |
Marketing (7)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Ani Pharmaceuticals | For profit | MKTG | Sep 30, 1992 |
| Ani Pharmaceuticals | For profit | NDA2 | Sep 30, 1992 |
| Fougera | For profit | NDA | Dec 30, 1998 |
| Fougera | For profit | NDA2 | Dec 30, 1988 |
| Sun Pharmaceuticals | For profit | MKTG | Mar 7, 2016 |
| Taro Pharmaceuticals | For profit | SYN | Mar 7, 2016 |
| Taro Pharmaceuticals | For profit | MKTG | Mar 7, 2016 |